Sporadic clone Escherichia coli ST615 as a vector and reservoir for dissemination of crucial antimicrobial resistance genes.

There is scarce information concerning the role of sporadic clones in the dissemination of antimicrobial resistance genes (ARGs) within the nosocomial niche. We confirmed that the clinical Escherichia coli M19736 ST615 strain, one of the first isolates of Latin America that harbors a plasmid with an mcr-1 gene, could receive crucial ARG by transformation and conjugation using as donors critical plasmids that harbor bla CTX-M-15, bla KPC-2, bla NDM-5, bla NDM-1, or aadB genes. Escherichia coli M19736 acquired bla CTX-M-15, bla KPC-2, bla NDM-5, bla NDM-1, and aadB genes, being only blaNDM-1 maintained at 100% on the 10th day of subculture. In addition, when the evolved MDR-E. coli M19736 acquired sequentially bla CTX-M-15 and bla NDM-1 genes, the maintenance pattern of the plasmids changed. In addition, when the evolved XDR-E. coli M19736 acquired in an ulterior step the paadB plasmid, a different pattern of the plasmid's maintenance was found. Interestingly, the evolved E. coli M19736 strains disseminated simultaneously the acquired conjugative plasmids in different combinations though selection was ceftazidime in all cases. Finally, we isolated and characterized the extracellular vesicles (EVs) from the native and evolved XDR-E. coli M19736 strains. Interestingly, EVs from the evolved XDR-E. coli M19736 harbored bla CTX-M-15 though the pDCAG1-CTX-M-15 was previously lost as shown by WGS and experiments, suggesting that EV could be a relevant reservoir of ARG for susceptible bacteria. These results evidenced the genetic plasticity of a sporadic clone of E. coli such as ST615 that could play a relevant transitional link in the clinical dynamics and evolution to multidrug/extensively/pandrug-resistant phenotypes of superbugs within the nosocomial niche by acting simultaneously as a vector and reservoir of multiple ARGs which later could be disseminated.

Comparación del cultivo celular de HeLa y HEp-2: Perspectivas de estudios con Chlamydia trachomatis / Comparison of cell culture HeLa and HEp-2: Studies prospects Chlamydia trachomatis

Objetivo. Estandarizar el cultivo de células HeLa en diferentes condiciones, con el fin de utilizarlo en protocolos de infección con Chlamydia trachomatis serovar L2. Materiales y métodos. Este estudio se llevó a cabo en cuatro fases principales que son: 1.Viabilidad celular por la técnica de azul de tripán y su posterior observación, 2. Estandarización del cultivo de células HeLa, 3. Coloración de Giemsa, 4. Cultivo de células HEp-2.Resultados. Se determinó que la línea celular HeLa debe ser cultivada en medio DMEM, 0,1% de L- glutamina, 10% de SFB. Así mismo, que la coloración de Giemsa es mejor realizarla en un tiempo de 40 minutos por que se evidencia una clara definición de núcleo y citoplasma. Frente a la comparación de las dos líneas celulares se obtuvo que la línea HeLa desde el primer día muestra un crecimiento adecuado y alcanza rápidamente la confluencia esperada, en contraposición la línea HEp-2 presenta un crecimiento más lento pero alcanzando la confluencia deseada al último día.

Objective. The goal of this study was to standardize the cultivation of HeLa cells under different conditions, to be used in Chlamydia trachomatis serovar L2 infection's protocols. Materials and Methods. This study was conducted in four phases that are: 1.Cell Viabilidad by trypan blue technique and his subsequent remark, 2. Standardization HeLa cell culture, 3. Giemsa, 4. Cultivation of Hep-2 cells. Results. As a result of standardization it is determined that the HeLa cell line should be cultured in DMEM, 0.1% L-glutamine, 10% FBS.It was determined that the Giemsa perform better over time of 40 minutes that a clear definition of nucleus and cytoplasm is evident. Comparing against both cell lines HeLa was obtained that the line from day growing well and quickly reaches the expected confluence, the opposed line HEp-2 has a slower growth but achieving the desired confluence the last day.